Limited Competition: Revision to the Coordinating Center for Type 1 Diabetes TrialNet (U01 Clinical Trial Required) | RFA DK 20 508

Opportunity Information: Apply for RFA DK 20 508

The NIH funding opportunity titled "Limited Competition: Revision to the Coordinating Center for Type 1 Diabetes TrialNet (U01 Clinical Trial Required)" (RFA-DK-20-508; CFDA 93.847) is a discretionary grant mechanism issued as a cooperative agreement. It is focused on strengthening the infrastructure and support needed to design and run new clinical intervention studies through the Type 1 Diabetes TrialNet network, a large, established research consortium dedicated to preventing, delaying, and improving outcomes in type 1 diabetes (T1D). T1D is described as a serious, lifelong disease that commonly begins in childhood or young adulthood, and the FOA is framed around the idea that scientific progress in understanding T1D biology and trial results have created timely opportunities to test therapies earlier in the disease process.

The main purpose of this FOA is to provide resources for the design and conduct of new intervention trials in two key populations: people at early, pre-clinical stages of T1D (before full diagnosis, when risk and immune activity can often be detected) and individuals with new-onset T1D (shortly after diagnosis, when preserving remaining insulin-producing beta cell function may still be possible). Rather than building a new network, the opportunity is specifically meant to support and revise activities within TrialNet by enhancing the operational capacity to launch and manage these studies efficiently and rigorously.

A defining feature is that it is a limited competition. The FOA invites an application from the Program Director/Principal Investigator of the TrialNet Coordinating Center (TNCC) that is currently supporting TrialNet research, meaning the competition is effectively restricted to the existing coordinating center leadership rather than open broadly to new coordinating centers. The emphasis is on continuity and leveraging an already functioning platform, while adding or adjusting resources so the network can take on additional or evolving intervention studies.

The TrialNet Coordinating Center is presented as the backbone of the network, with responsibilities that span scientific leadership, trial operations, and analytic support. Specifically, the TNCC is expected to provide leadership in study design and monitoring, support clinical and laboratory testing required for trial conduct, and maintain systems for data collection and processing. It also supports biostatistical analysis and the administrative operations that keep multi-site, multi-protocol clinical research running smoothly. In practice, this kind of coordinating center role usually involves harmonizing procedures across sites, ensuring protocol compliance, managing data quality, overseeing safety monitoring processes, and coordinating communications and reporting among investigators, laboratories, and NIH program staff, consistent with the cooperative agreement model where NIH typically has substantial programmatic involvement.

Eligibility information included in the source text lists a broad set of applicant types in general NIH terms, including various levels of government (state, county, city/township, special districts), public and private institutions of higher education, independent school districts, federally recognized Native American tribal governments, tribal organizations (including those other than federally recognized tribal governments), public housing authorities/Indian housing authorities, nonprofits (both 501(c)(3) and non-501(c)(3)), for-profit organizations (other than small businesses), and small businesses, along with an "Others" category. The FOA also explicitly notes inclusion of certain institution types and organizations such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving Institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISISs), eligible federal agencies, faith-based or community-based organizations, regional organizations, and U.S. territories or possessions. Despite this broad eligibility language, the limited-competition nature of the announcement makes clear that the intended applicant is the current TNCC Program Director/Principal Investigator.

Restrictions on non-U.S. involvement are stated clearly. Non-domestic (non-U.S.) entities and non-domestic components of U.S. organizations are not eligible to apply. However, foreign components, as defined in the NIH Grants Policy Statement, are allowed. This typically means the applicant organization must be U.S.-based and eligible, but certain parts of the work may involve foreign collaborations or activities if they meet NIH requirements for foreign components and are justified and approved.

Key administrative details from the source include that the funding instrument is a cooperative agreement (U01), the activity category is health (also tagged under food and nutrition, health), and the agency is the National Institutes of Health. The opportunity was created on January 7, 2021, with an original closing date of April 14, 2021. The provided excerpt does not specify an award ceiling, expected number of awards, or total budget, indicating those details were either not included in the snapshot or were unspecified in the extracted fields.

Overall, the FOA is best understood as targeted support for the existing TrialNet Coordinating Center to expand or adapt TrialNet's capacity to run intervention trials aimed at preventing or delaying the onset of T1D and improving outcomes close to diagnosis. It prioritizes network-level capabilities such as trial design leadership, clinical and laboratory operational support, robust data systems, statistical analysis, and administrative coordination, all of which are essential for conducting complex, multi-site clinical trials in early and newly diagnosed T1D populations.

• The National Institutes of Health in the food and nutrition, health sector is offering a public funding opportunity titled "Limited Competition: Revision to the Coordinating Center for Type 1 Diabetes TrialNet (U01 Clinical Trial Required)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.847.
• This funding opportunity was created on 2021-01-07.
• Applicants must submit their applications by 2021-04-14. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.

Apply for RFA DK 20 508

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: